Product
DVX201
2 clinical trials
4 indications
Indication
acute myeloid leukemiaIndication
Adult RecurrentIndication
MDSIndication
COVID-19 PneumoniaClinical trial
An Open-Label Pilot Study to Evaluate the Safety and Efficacy of DVX201 NK Cells in Patients With Relapsed or Refractory AML or High Risk MDS or High Risk Overlapping Myelodysplastic / Myeloproliferative NeoplasmsStatus: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
A Phase 1 Study of DVX201, an Allogeneic Natural Killer (NK) Cell Therapy in Subjects Hospitalized for COVID-19Status: Completed, Estimated PCD: 2022-06-07